671 related articles for article (PubMed ID: 34768911)
61. Potential Antiviral Immune Response Against COVID-19: Lessons Learned from SARS-CoV.
Akbarpour M; Sharifi L; Safdarian AR; Farhangnia P; Borjkhani M; Rezaei N
Adv Exp Med Biol; 2021; 1318():149-167. PubMed ID: 33973177
[TBL] [Abstract][Full Text] [Related]
62. Gut microbiome, Vitamin D, ACE2 interactions are critical factors in immune-senescence and inflammaging: key for vaccine response and severity of COVID-19 infection.
Shenoy S
Inflamm Res; 2022 Jan; 71(1):13-26. PubMed ID: 34738147
[TBL] [Abstract][Full Text] [Related]
63. A review on the immune responses against novel emerging coronavirus (SARS-CoV-2).
Lotfi R; Kalmarzi RN; Roghani SA
Immunol Res; 2021 Jun; 69(3):213-224. PubMed ID: 33928531
[TBL] [Abstract][Full Text] [Related]
64. Statins and Covid-19: The Neglected Front of bidirectional effects.
Hussien NR; Al-Niemi MS; Al-Kuraishy HM; Al-Gareeb AI
J Pak Med Assoc; 2021 Dec; 71(Suppl 8)(12):S133-S136. PubMed ID: 35130236
[TBL] [Abstract][Full Text] [Related]
65. SARS-CoV 2; Possible alternative virus receptors and pathophysiological determinants.
Pruimboom L
Med Hypotheses; 2021 Jan; 146():110368. PubMed ID: 33189453
[TBL] [Abstract][Full Text] [Related]
66. The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology.
Sohaei D; Hollenberg M; Janket SJ; Diamandis EP; Poda G; Prassas I
Crit Rev Clin Lab Sci; 2023 Jan; 60(1):25-40. PubMed ID: 35930434
[TBL] [Abstract][Full Text] [Related]
67. Hypoxia induces expression of angiotensin-converting enzyme II in alveolar epithelial cells: Implications for the pathogenesis of acute lung injury in COVID-19.
Sturrock A; Zimmerman E; Helms M; Liou TG; Paine R
Physiol Rep; 2021 May; 9(9):e14854. PubMed ID: 33991451
[TBL] [Abstract][Full Text] [Related]
68. Coronavirus infection: An immunologists' perspective.
De Sanctis JB; García AH; Moreno D; Hajduch M
Scand J Immunol; 2021 Jun; 93(6):e13043. PubMed ID: 33783027
[TBL] [Abstract][Full Text] [Related]
69. The use of human iPSC-derived alveolar organoids to explore SARS-CoV-2 variant infections and host responses.
Gandikota C; Vaddadi K; Sivasami P; Huang C; Liang Y; Pushparaj S; Deng X; Channappanava R; Metcalf JP; Liu L
J Med Virol; 2024 Apr; 96(4):e29579. PubMed ID: 38572923
[TBL] [Abstract][Full Text] [Related]
70. Repurposing Methotrexate in Dampening SARS-CoV2-S1-Mediated IL6 Expression: Lessons Learnt from Lung Cancer.
Gowda P; Patrick S; Joshi SD; Kumawat RK; Sen E
Inflammation; 2022 Feb; 45(1):172-179. PubMed ID: 34480250
[TBL] [Abstract][Full Text] [Related]
71. Controlling Cytokine Storm Is Vital in COVID-19.
Tang L; Yin Z; Hu Y; Mei H
Front Immunol; 2020; 11():570993. PubMed ID: 33329533
[TBL] [Abstract][Full Text] [Related]
72. The Impact of ACE2 Polymorphisms on COVID-19 Disease: Susceptibility, Severity, and Therapy.
Chen F; Zhang Y; Li X; Li W; Liu X; Xue X
Front Cell Infect Microbiol; 2021; 11():753721. PubMed ID: 34746028
[TBL] [Abstract][Full Text] [Related]
73. Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions.
Abdelmoaty MM; Yeapuri P; Machhi J; Olson KE; Shahjin F; Kumar V; Zhou Y; Liang J; Pandey K; Acharya A; Byrareddy SN; Mosley RL; Gendelman HE
Front Immunol; 2021; 12():741502. PubMed ID: 34671355
[TBL] [Abstract][Full Text] [Related]
74. Emerging neurotropic features of SARS-CoV-2.
Zhan WR; Huang J; Zeng PM; Tian WY; Luo ZG
J Mol Cell Biol; 2021 Dec; 13(10):705-711. PubMed ID: 34289037
[TBL] [Abstract][Full Text] [Related]
75. Coronaviruses: Innate Immunity, Inflammasome Activation, Inflammatory Cell Death, and Cytokines.
Lee S; Channappanavar R; Kanneganti TD
Trends Immunol; 2020 Dec; 41(12):1083-1099. PubMed ID: 33153908
[TBL] [Abstract][Full Text] [Related]
76. Relationship Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Etiology of Acute Kidney Injury (AKI).
Chong WH; Saha BK
Am J Med Sci; 2021 Mar; 361(3):287-296. PubMed ID: 33358501
[TBL] [Abstract][Full Text] [Related]
77. The potential involvement of JAK-STAT signaling pathway in the COVID-19 infection assisted by ACE2.
Luo J; Lu S; Yu M; Zhu L; Zhu C; Li C; Fang J; Zhu X; Wang X
Gene; 2021 Feb; 768():145325. PubMed ID: 33253796
[TBL] [Abstract][Full Text] [Related]
78. Vitamin D and COVID-19: Role of ACE2, age, gender, and ethnicity.
Getachew B; Tizabi Y
J Med Virol; 2021 Sep; 93(9):5285-5294. PubMed ID: 33990955
[TBL] [Abstract][Full Text] [Related]
79. Human Lung Stem Cell-Based Alveolospheres Provide Insights into SARS-CoV-2-Mediated Interferon Responses and Pneumocyte Dysfunction.
Katsura H; Sontake V; Tata A; Kobayashi Y; Edwards CE; Heaton BE; Konkimalla A; Asakura T; Mikami Y; Fritch EJ; Lee PJ; Heaton NS; Boucher RC; Randell SH; Baric RS; Tata PR
Cell Stem Cell; 2020 Dec; 27(6):890-904.e8. PubMed ID: 33128895
[TBL] [Abstract][Full Text] [Related]
80. Expression of the readthrough transcript CiDRE in alveolar macrophages boosts SARS-CoV-2 susceptibility and promotes COVID-19 severity.
Mitsui Y; Suzuki T; Kuniyoshi K; Inamo J; Yamaguchi K; Komuro M; Watanabe J; Edamoto M; Li S; Kouno T; Oba S; Hosoya T; Masuhiro K; Naito Y; Koyama S; Sakaguchi N; Standley DM; Shin JW; Akira S; Yasuda S; Miyazaki Y; Kochi Y; Kumanogoh A; Okamoto T; Satoh T
Immunity; 2023 Aug; 56(8):1939-1954.e12. PubMed ID: 37442134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
